<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>

</head>
<body>
  <h1>High mid-treatment tumour RNA disruption in patients with HER2-negative breastcancer is associated with improved disease-free survival after neoadjuvantchemotherapy - PMC</h1>
  
  <div class="share-block">
    <span>üîó ÂàÜ‰∫´ÈÄôÁØáÊëòË¶ÅÔºö</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-summary.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-summary.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fhigh-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-summary.html&text=High%20mid-treatment%20tumour%20RNA%20disruption%20in%20patients%20with%20HER2-negative%20breastcancer%20is%20associated%20with%20improved%20disease-free%20survival%20after%20neoadjuvantchemotherapy%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  <div style="text-align: center;"><img src="https://i.imgur.com/H4JFuyI.png" alt="News Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;"></div>
  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">‰∏≠Êñá</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">Êó•Êú¨Ë™û</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        Âª£Âëä
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style="">Okay, here's a breakdown of the information extracted from the provided text, organized for clarity.  I'm focusing on the key data points and references.

**Overall Article Focus:**

The text appears to be an excerpt from a research article concerning neoadjuvant chemotherapy (chemotherapy given *before* surgery) for breast cancer, specifically focusing on factors influencing response and outcomes.

**Key References & Findings (Summarized):**

Here's a list of the cited studies and the general findings they represent, as described in the text.  I'm including the authors and year for easy reference.

1.  **Cortazar et al. (2014):**  This study (CTNeoBC pooled analysis) investigated the relationship between pathological complete response (pCR) and long-term clinical benefit in breast cancer.
2.  **Sinn et al. (2024):** This study examined the use of on-treatment biopsies to predict response to neoadjuvant chemotherapy.
3.  **Ribatti et al. (2020):** Provides a historical overview of Epithelial-Mesenchymal Transition (EMT) in cancer.
4.  **Zhao et al. (2022):**  This metaanalysis explored the prognostic value of circulating tumor cells (CTCs) exhibiting EMT in female breast cancer.
5.  **Nahleh et al. (2019):**  A metaanalysis of randomized controlled trials evaluating the use of bevacizumab (a drug targeting angiogenesis) in the neoadjuvant treatment of HER2-negative breast cancer.
6.  **Earl et al. (2017):**  This study examined the impact of bevacizumab added to docetaxel followed by other chemotherapy drugs on disease-free and overall survival in women with HER2-negative early breast cancer (ARTemis trial).
7.  **Cortazar et al. (2014):**  Investigated the relationship between pathological complete response (pCR) and long-term clinical benefit in breast cancer.
8.  **Sinn et al. (2024):** Examined the use of on-treatment biopsies to predict response to neoadjuvant chemotherapy.

**Data Availability:**

*   Raw data supporting the article's results can be found in Supplemental Data Files 1, 2, and 3.
*   Access to NeoAva materials and data is governed by its principal investigator, Dr. Olav Engebraaten.

**Supplementary Materials:**

The article includes several supplementary materials:

*   Supplemental Data File 1 (PDF)
*   Supplemental Data File 2 (XLSX)
*   Supplemental Data File 3 (XLSX)
*   Supplemental Data File 4 (TIFF image)
*   Supplemental Data File 5 (TIFF image)
*   Supplemental Data File 6 (TIFF image)
*   Supplemental Data File 7 (DOCX)

**Important Notes:**

*   **HER2-Negative Breast Cancer:**  Several studies specifically focus on breast cancer that is HER2-negative, indicating a particular subtype.
*   **Neoadjuvant Chemotherapy:**  The central theme is the use of chemotherapy *before* surgery to shrink tumors and assess response.
*   **Pathological Complete Response (pCR):**  A key outcome measure, referring to the absence of cancer cells in the tumor after neoadjuvant chemotherapy.
*   **EMT and CTCs:**  The article touches on the roles of EMT (a process where cancer cells become more mobile and invasive) and CTCs (circulating tumor cells) in cancer progression and response to therapy.

Let me know if you'd like me to elaborate on any of these points or extract other information from the text!</div><div class="lang-content" data-lang="en" style="display: none;">Okay, here's a breakdown of the references listed in the provided text, formatted for clarity.  I'm including the full citation as it appears, and a brief note about what the reference seems to be about.

**References from the Provided Text**

1.  **Nahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2negative breast cancer A metaanalysis of randomized controlled trials. Mol Clin Oncol. 20191035765. DOI httpsdoi.org10.3892mco.2019.1796 PMC free article articlesPMC6388502 PubMed httpspubmed.ncbi.nlm.nih.gov30847174 Google Scholar httpsscholar.google.comscholar_lookupNahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2negative breast cancer A metaanalysis of randomized controlled trials. Mol Clin Oncol. 20191035765. DOI httpsdoi.org10.3892mco.2019.1796 PMC free article articlesPMC6388502 PubMed httpspubmed.ncbi.nlm.nih.gov30847174 Google Scholar httpsscholar.google.comscholar_lookup**
    *   **About:** A meta-analysis (a study that combines the results of multiple studies) examining the use of bevacizumab (a drug) in the neoadjuvant (treatment given before surgery) setting for breast cancer that doesn't have HER2.

2.  **Ribatti D, Tamma R, Annese T. EpithelialMesenchymal transition in cancer A historical overview. Transl Oncol. 202013100773. DOI httpsdoi.org10.1016j.tranon.2020.100773 PMC free article articlesPMC7182759 PubMed httpspubmed.ncbi.nlm.nih.gov32334405 Google Scholar httpsscholar.google.comscholar_lookupRibatti D, Tamma R, Annese T. EpithelialMesenchymal transition in cancer A historical overview. Transl Oncol. 202013100773. DOI httpsdoi.org10.1016j.tranon.2020.100773 PMC free article articlesPMC7182759 PubMed httpspubmed.ncbi.nlm.nih.gov32334405 Google Scholar httpsscholar.google.comscholar_lookup**
    *   **About:** A review article providing historical context for the process of epithelial-mesenchymal transition (EMT) in cancer.

3.  **Zhao Q, Li B, Gao Q, Luo Y, Ming L. Prognostic value of epithelialmesenchymal transition Circulating tumor cells in female breast cancer A metaanalysis. Front Oncol. 2022121024783. DOI httpsdoi.org10.3389fonc.2022.1024783 PMC free article articlesPMC9749886 PubMed httpspubmed.ncbi.nlm.nih.gov36530995 Google Scholar httpsscholar.google.comscholar_lookupZhao Q, Li B, Gao Q, Luo Y, Ming L. Prognostic value of epithelialmesenchymal transition Circulating tumor cells in female breast cancer A metaanalysis. Front Oncol. 2022121024783. DOI httpsdoi.org10.3389fonc.2022.1024783 PMC free article articlesPMC9749886 PubMed httpspubmed.ncbi.nlm.nih.gov36530995 Google Scholar httpsscholar.google.comscholar_lookup**
    *   **About:** A meta-analysis examining the prognostic (predictive of outcome) value of circulating tumor cells undergoing EMT in breast cancer.

4.  **Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and longterm clinical benefit in breast cancer the CTNeoBC pooled analysis. Lancet. 201438416472. DOI httpsdoi.org10.1016S01406736624228 PubMed httpspubmed.ncbi.nlm.nih.gov24529560 Google Scholar httpsscholar.google.comscholar_lookupCortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and longterm clinical benefit in breast cancer the CTNeoBC pooled analysis. Lancet. 201438416472. DOI httpsdoi.org10.1016S01406736624228 PubMed httpspubmed.ncbi.nlm.nih.gov24529560 Google Scholar httpsscholar.google.comscholar_lookup**
    *   **About:** A study analyzing pathological complete response (no cancer found after surgery) and long-term clinical benefit in breast cancer, using pooled data from the CTNeoBC study.

5.  **Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, et al. Ontreatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 202426138. DOI httpsdoi.org10.1186s13058025_2025_2092_MOESM1_ESM.pdf Supplementary Material 2articlesinstance12337404bin13058_2025_2092_MOESM2_ESM.xlsx Supplementary Material 3articlesinstance12337404bin13058_2025_2092_MOESM3_ESM.xlsx Supplementary Material 4articlesinstance12337404bin13058_2025_2092_MOESM4_ESM.tif Supplementary Material 5articlesinstance12337404bin13058_2025_2092_MOESM5_ESM.tif Supplementary Material 6articlesinstance12337404bin13058_2025_2092_MOESM6_ESM.tif Supplementary Material 7articlesinstance12337404bin13058_2025_2092_MOESM7_ESM.docx ASSOCIATED DATAThis section collects any data citations, data availability statements, orsupplementary materials included in this article.SUPPLEMENTARY MATERIALSSupplementary Material 1articlesinstance12337404bin13058_2025_2092_MOESM1_ESM.pdf Supplementary Material 2articlesinstance12337404bin13058_2025_2092_MOESM2_ESM.xlsx Supplementary Material 3articlesinstance12337404bin13058_2025_2092_MOESM3_ESM.xlsx Supplementary Material 4articlesinstance12337404bin13058_2025_2092_MOESM4_ESM.tif Supplementary Material 5articlesinstance12337404bin13058_2025_2092_MOESM5_ESM.tif Supplementary Material 6articlesinstance12337404bin13058_2025_2092_MOESM6_ESM.tif Supplementary Material 7articlesinstance12337404bin13058_2025_2092_MOESM7_ESM.docx DATA AVAILABILITY STATEMENTThe raw data supporting the results reported in this article can be found inSupplemental Data Files 1, 2, and 3. Access to NeoAva materials and data isgoverned by its principal investigator Dr. Olav Engebraaten.\n URL: https://pmc.ncbi.nlm.nih.gov/articles/12337404/"
    *   **About:** A study examining the use of on-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.

**Note:** The provided text also mentions "NeoAva materials and data" and a principal investigator, Dr. Olav Engebraaten, but these are not formal references.  The supplementary materials are also listed, but are not formal references.

Let me know if you'd like any of these references elaborated on further!</div><div class="lang-content" data-lang="jp" style="display: none;">Okay, here's a breakdown of the information extracted from the provided text, organized for clarity.  I'm focusing on the key data points and references.

**1. Article Information (Implied)**

*   **Journal:** Breast Cancer Research (Based on citations and references)
*   **Year:** 2025 (Based on citations and references)
*   **Article ID:** 12337404
*   **Focus:** Neoadjuvant therapy (treatment before surgery) for breast cancer, particularly focusing on response prediction and the role of biomarkers.

**2. Key Findings & Topics Discussed (Based on References & Descriptions)**

*   **Pathological Complete Response (pCR):** A major endpoint in neoadjuvant therapy trials.  Several studies (Cortazar et al., 2014; Sinn et al., 2024) highlight the importance of pCR and its association with long-term clinical benefit.
*   **Biomarkers & Response Prediction:** The article explores the use of biomarkers to predict how patients will respond to neoadjuvant chemotherapy.
    *   **Epithelial-Mesenchymal Transition (EMT):**  EMT is discussed as a process relevant to cancer progression and response to therapy (Ribatti et al., 2020; Zhao et al., 2022).
    *   **Circulating Tumor Cells (CTCs):**  The prognostic value of EMT-related CTCs is examined (Zhao et al., 2022).
    *   **Ontreatment Biopsies:**  The use of biopsies taken during treatment to assess response is highlighted (Sinn et al., 2024).
*   **Bevacizumab:**  The role of bevacizumab (an anti-VEGF antibody) in neoadjuvant treatment is discussed (Nahleh et al., 2019; Earl et al., 2017).
*   **Clinical Trials & Pooled Analyses:**  Several clinical trials and pooled analyses are referenced to support the findings (Cortazar et al., 2014; CTNeoBC pooled analysis).

**3. Referenced Studies (with Full Citations)**

*   **Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and longterm clinical benefit in breast cancer the CTNeoBC pooled analysis. Lancet. 2014;384:1647-1652.**
*   **Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Gounaris I, Abraham JE, HughesDavies L, McAdam K, et al. Diseasefree and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer ARTemis trial. Ann Oncol. 2017;28:1817-1824.**
*   **Nahleh Z, Botrus G, Dwivedi A, Jennings M, Nagy S, Tfayli A. Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2negative breast cancer A metaanalysis of randomized controlled trials. Mol Clin Oncol. 2019;10:357-365.**
*   **Ribatti D, Tamma R, Annese T. EpithelialMesenchymal transition in cancer A historical overview. Transl Oncol. 2020;13:100773.**
*   **Zhao Q, Li B, Gao Q, Luo Y, Ming L. Prognostic value of epithelialmesenchymal transition Circulating tumor cells in female breast cancer A metaanalysis. Front Oncol. 2022;12:1024783.**
*   **Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, et al. Ontreatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. 2024;26:138.**

**4. Data Availability**

*   Raw data supporting the article can be found in Supplemental Data Files 1, 3, and 4.
*   Access to NeoAva materials and data is governed by Dr. Olav Engebraaten.

**5. Supplementary Materials**

*   Several supplementary materials are listed (PDF, XLSX, TIF, DOCX) ‚Äì likely containing additional data, figures, or tables.

Let me know if you're interested in a more detailed breakdown of any specific aspect of this information!</div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="./high-midtreatment-tumour-rna-disruption-in-patients-with-her2negative-breastcancer-is-associated-with-improved-diseasefree-survival-after-neoadjuvantchemotherapy-pmc-seo.html">üëâ Êü•ÁúãÂéüÊñá / Full Article</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>